$0.82
-0.02 (-2.93%)
Open$0.84
Previous Close$0.84
Day High$0.85
Day Low$0.82
52W High$24.30
52W Low$0.78
Volume—
Avg Volume180.8K
Market Cap3.27M
P/E Ratio—
EPS$-10.03
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,923.5% upside
Current
$0.82
$0.82
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 339.47M | 953.7K | 857.2K |
| Net Income | -55,871,294 | 90.7K | 81.5K |
| Profit Margin | -16.5% | 9.5% | 9.5% |
| EBITDA | -55,119,932 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +102.9% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |